[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100371079":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":18,"responsibleParty":39,"collaborators":7,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":7,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":7,"studyType":55,"phases":7,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Mayo Clinic","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Marie Hogan, MD, PhD","PRINCIPAL_INVESTIGATOR",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Cassie Howe, CRC","CONTACT","507-266-1230","howe.cassie@mayo.edu",[19],{"facility":5,"status":20,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":27,"coordinates":28},"Point",[29,30],-92.4699,44.02163,{"lat":30,"lon":29},[33,37],{"name":34,"role":15,"phone":35,"phoneExt":7,"email":36},"Marie C Hogan, MD, PhD","507-266-1963","hogan.marie@mayo.edu",{"name":38,"role":11,"phone":7,"phoneExt":7,"email":7},"Marie C. Hogan, M.D., Ph.D.",{"type":11,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Marie Hogan","Principal Investigator","100371079","a-prospective-observational-study-of-foam-sclerotherapy--100371079",false,"NCT04111692","A Prospective Observational Study of Foam Sclerotherapy .","A Prospective Observational Study of Foam Sclerotherapy for the Treatment of Symptomatic Kidney or Liver Cysts in Patients With Autosomal Dominant Polycystic Kidney and Liver Disease.","Inclusion Criteria:\n\n* Age ≥18 years\n* Clinical diagnosis of ADPKD or ADPLD\n* 1-3 large, non-exophytic liver or kidney cyst\n* Compressive symptoms from dominant cyst\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Absence of ADPKD or ADPLD\n* Largest cyst \\\u003C4cm in all 3 dimensions or largest cyst volume \\\u003C400cc\n* \\>3 large, non-exophytic liver or kidney cyst(s) ≥4cm in all 3 dimensions (cyst volume ≥400cc)\n* Unwilling to comply with study follow-up protocol to 12 ± 1months post-FS\n* Lacking capacity to provide informed consent to FS of liver or kidney cysts\n* Pregnancy","ALL","18 Years","100 Years",{"count":53,"type":54},100,"ESTIMATED","OBSERVATIONAL","An observational prospective study to determine the impact of foam sclerotherapy of large, dominant kidney\u002Fliver cysts on quality of life outcomes and kidney\u002Fliver cyst volumes at up to 12 months of follow-up in patients with autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD).",[58,59,60,61],"Autosomal Dominant Polycystic Kidney","Renal Cyst","Autosomal Dominant Polycystic Liver Disease","Hepatic Cyst",[63,64,65,66],"hepatic cyst","Kidney Cyst","Autosomal Polycystic Liver Disease","Autosomal Polycystic Kidney Disease","2026-01-22",{"date":69,"type":70},"2026-01-26","ACTUAL",{"date":72,"type":70},"2017-11-06",{"date":74,"type":54},"2027-11",{"name":5,"class":6},1]